Gregory Glenn
Nessuna posizione attualmente
Patrimonio netto: 87 660 $ in data 31/03/2024
Profilo
Gregory M. Glenn ha fondato Intercell USA, Inc. Il dott. Glenn è presidente della ricerca e sviluppo presso Novavax, Inc. In precedenza ha occupato la posizione di responsabile scientifico di Intercell AG, responsabile scientifico e vicepresidente senior di Intercell USA, Inc., ricercatore presso il Walter Reed Army Institute of Research e Associate-International Health alla Johns Hopkins Bloomberg School of Public Health. Il Dr. Glenn si è laureato al Whitman College e ha conseguito un dottorato alla Oral Roberts University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NOVAVAX, INC.
0.01% | 18/04/2023 | 18 339 ( 0.01% ) | 87 660 $ | 31/03/2024 |
Precedenti posizioni note di Gregory Glenn
| Società | Posizione | Fine |
|---|---|---|
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 31/03/2023 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 01/01/2010 |
| IOMAI CORPORATION | Founder | 01/01/2008 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
| Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - |
Formazione di Gregory Glenn
| Oral Roberts University | Doctorate Degree |
| Whitman College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
| Walter Reed Army Institute of Research |
- Borsa valori
- Insiders
- Gregory Glenn
